FEB 27, 2019 03:00 PM PST

Targeted Cancer Chemotherapy: Developing NextGen Antibody-Drug Conjugates

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Senior Vice President, Research & Development, ModMab Therapeutics, Inc.
    Biography
      Over 15 years of experience in oncology drug discovery and development/antibody therapeutics and more than 20 years of experience in the life science research as a biochemist/molecular cell biologist. Recognized in the scientific and pharmaceutical communities for inventing and developing a novel and innovative THIOMAB technology platform to obtain engineered ADCs with defined number of payloads per conjugate. Authored over 100 patents/peer-reviewed publications and have been a featured keynote speaker at many international high-profile scientific conferences. Led cross-functional teams in the discovery of innovative Antibody Dug Conjugates (ADCs) and Bi-specific cancer immunotherapeutic programs. Core member of launched T-DM1 (Kadcyla) R&D team. Led the teams, which discovered and developed a next generation site-specific T-DM1 ADC project and over 10 other ADC/Bi-specific antibody therapeutic candidates. Leveraged several cross-functional teams in discovery research, pre-clinical research and manufacturing to move antibody based therapeutic molecules from discovery to IND.

    Abstract:

    In today's presentation I will give an overview to developing NextGen ADCs. We will discuss everything from the beginning stages of development to the varying ADC combination therapies available. (There are currently 23 ADCs in total being studied in 45 combination trials with 10 different  immune checkpoint modulators).

    Learning Objectives: 

    1. This presentation will discuss past, present challenges associated with developing antibody-drug conjugates (ADCs), a novel modality of targeted cancer chemotherapy
    2. Presentation will also highlight key factors that influence in developing next generation ADCs. 


    Show Resources
    You May Also Like
    NOV 15, 2018 10:00 AM PST
    C.E. CREDITS
    NOV 15, 2018 10:00 AM PST
    DATE:  November 15, 2018TIME:  10:00am PT, 1:00pm ET Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the ana...
    FEB 26, 2019 09:00 AM PST
    C.E. CREDITS
    FEB 26, 2019 09:00 AM PST
    DATE:  February 26, 2019TIME:   9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
    FEB 20, 2019 09:00 AM PST
    C.E. CREDITS
    FEB 20, 2019 09:00 AM PST
    DATE:  February 20, 2019TIME:  9:00am PST  ...
    FEB 27, 2019 08:00 AM PST
    C.E. CREDITS
    FEB 27, 2019 08:00 AM PST
    DATE:  February 27, 2019TIME:  8:00am PST Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture...
    MAR 26, 2019 02:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAR 26, 2019 02:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
    OCT 09, 2018 08:00 AM PDT
    C.E. CREDITS
    OCT 09, 2018 08:00 AM PDT
    DATE: October 9, 2018TIME: 08:00am PDT, 11:00pm EDT Have you ever wondered what to consider when you are selecting ancillary materials for your cell therapy clinical research...
    Loading Comments...
    Show Resources